Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 17144 pages

Showing 6301 - 6350


multiple myeloma
covid-19

Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab

A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...

covid-19

$20 Million in Grants Awarded to Identify Therapies for COVID-19

The partners in the COVID-19 Therapeutics Accelerator—a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard—awarded $20 million in initial grants to three institutions. The University of Washington, the University of Oxford, and La Jolla Institute...

immunotherapy
symptom management

Treatment With Checkpoint Inhibitors May Cause Thyroid Dysfunction

Thyroid dysfunction following treatment with immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting (Abstract SAT-418), and that will be published in Journal of the Endocrine...

multiple myeloma
immunotherapy

Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing

Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...

genomics/genetics
solid tumors
hematologic malignancies

Methylation Signatures From Sequencing Circulating Cell-Free DNA Detected Different Types of Cancer Across Multiple Stages

Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated—often before there are any clinical signs or symptoms of the disease. These findings were published by Liu et al in Annals of Oncology. In their ...

covid-19

Clinical Trials to Evaluate Activity of Biologics, Other Agents Against COVID-19

In an effort to expedite research for agents with potential activity against symptoms associated with the novel coronavirus (COVID-19), the U.S. Food and Drug Administration (FDA) is evaluating and/or has approved a number of randomized clinical trials seeking to determine whether a drug has...

breast cancer

Indigenous American Ancestry May Be Associated With HER2-Positive Breast Cancer

An increased proportion of indigenous American ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research.1 “The risk of breast cancer–related mortality varies between different populations, with Latina women having a greater...

AACR Annual Meeting 2020 to Be Held in a Virtual-Only Format

Today, the American Association for Cancer Research (AACR) Board of Directors issued the following announcement: The AACR has been closely monitoring the rapid escalation of the COVID-19 pandemic. The health and safety of all Annual Meeting attendees and the patients and communities they serve are...

myelodysplastic syndromes
symptom management

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

On April 3, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) for the treatment of anemia that fails to respond to an erythropoiesis-stimulating agent and requires two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk...

issues in oncology
covid-19

Harvard Medical Student’s Innovation: Disinfection You Can See

In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...

breast cancer
bladder cancer
lymphoma
immunotherapy

FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations

The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...

issues in oncology

Apixaban for Cancer-Associated Venous Thromboembolism

For patients with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low–molecular-weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), with no excess in major bleeding events. These findings from the phase III Caravaggio study were...

covid-19

Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD

During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...

hematologic malignancies
covid-19

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

On April 1, the ASH Research Collaborative's (ASH RC) Data Hub launched the ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy, a global registry with clinical data exclusively on people with COVID-19 and a current or past diagnosis of a hematologic malignancy. The registry is intended to ...

issues in oncology
gynecologic cancers
global cancer care

Gynecologic Cancer Screening After a Natural Disaster

Cervical cancer screening rates were significantly affected in the years following the Great East Japan Earthquake of 2011, according to a report published by Miki et al in PLOS ONE. “Conflicts and disasters, and the social isolation that often follows, have a major impact on health care and lead...

issues in oncology
lung cancer

Disparities in Receipt of Chemotherapy Among Patients With pN1 Lung Cancer

In patients with non–small cell lung cancer (NSCLC) where the cancer has spread to one or more lymph nodes close to the lungs—a condition known as pathologic N1 (pN1) disease—current guidelines recommend a two-part protocol: surgical resection, followed by chemotherapy. However, a retrospective...

multiple myeloma
covid-19

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver...

issues in oncology
geriatric oncology

Polypharmacy and Inpatient Hospitalization Rates in Older Patients With Cancer

In a study published by Grace Lu-Yao, PhD, and colleagues in the Journal of Geriatric Oncology, researchers found hospitalization rates can increase by as much as 114% in patients with breast, prostate, and lung cancers when those patients have taken 15 or more medications prior to chemotherapy...

solid tumors
immunotherapy

Does Pembrolizumab Show Activity in Some Rare Cancers?

A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated acceptable toxicity and antitumor activity in patients with four types of advanced, hard-to-treat rare cancers. “Our findings that pembrolizumab has a favorable toxicity...

immunotherapy
lung cancer

FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC

On March 27, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). CASPIAN Trial Efficacy of this combination in patients...

Cancer Care Amid the COVID-19 Pandemic

To start off this week, we’ll discuss a report from physicians in Washington state about how they’re handling cancer care currently in their institutions amid the COVID-19 pandemic. We’ll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy...

hepatobiliary cancer
global cancer care

Trends in Global Rates of Liver Cancer From 1990 to 2017

New research published by Liu et al in the journal Cancer has revealed rising rates of liver cancer around the world, despite advances aimed at preventing the disease; however, some steps towards alleviation have been made due to control of hepatitis. Methods To obtain trends and estimates of liver ...

covid-19

American College of Surgeons Issues COVID-19 Guidelines for Triage of Patients Undergoing Cancer Surgery

This week, the American College of Surgeons issued guidelines on triage of patients undergoing elective cancer surgery during the COVID-19 pandemic. During the current COVID-19 pandemic, hospital leadership and individual providers are facing increasingly difficult decisions about how to conserve...

global cancer care
covid-19

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they treat patients with cancer. Filmed March 24, 2020.

covid-19

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia

Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.

gynecologic cancers
immunotherapy

Predicting Which Patients With Ovarian Cancer May Respond to Combination PARP and PD-1 Inhibition

In some patients with advanced ovarian cancer, the combination of programmed cell death protein 1 (PD-1) and poly (ADP-ribose) polymerase (PARP) inhibitors can produce responses, but up until now, investigators have been unable to predict which patients would not benefit from the treatment and...

covid-19

Association for Clinical Oncology: More Testing, Personal Protective Equipment, Practice Support Needed During COVID-19 Crisis

The Association for Clinical Oncology, ASCO's affiliated 501(c)(6) organization, is urging the White House and leaders in Congress to swiftly work together to meet the needs of patients and health-care professionals in response to the COVID-19 crisis. In a letter to the President, Vice President,...

ASCO, Project ECHO Partner to Pilot Impactful Cancer Tele-Education Program in Nepal

Cancer care for patients in rural areas is challenging—for example, in the United States, only 3% of medical oncologists practice in rural areas, and patients must travel long distances to see specialists. Patients may also have trouble managing complications from care or follow-up from treatment....

The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early-Career Researchers

The parker institute for cancer immunotherapy (PICI) recently announced awards for six early-career researchers through the Parker Scholars, Parker Bridge Fellows, and Parker Senior Fellows programs. They are receiving a total of up to $2.75 million in funding to advance their research in profound...

breast cancer
issues in oncology

Don’t Expect Transgender Patients to ‘Out’ Themselves

Although more transgender patients are presenting to breast centers for imaging, many “report significant social stigma when seeking care,” according to a study in the Journal of Breast Imaging.1 Reported verbal abuse and other forms of harassment “can lead to transgender patients concealing their...

breast cancer
issues in oncology

Addressing the Needs of Transgender Patients for Breast Cancer Screening in Comfortable and Inclusive Environments

An analysis of breast imaging center websites and a literature search for research articles on transgender breast health found that “issues related to transgender breast imaging are not well addressed in the radiology literature or in the radiology community, even though more transgender patients...

breast cancer

I Wasn’t Prepared for the Emotional Turmoil of Breast Cancer

Nearly a decade ago, my mother tested positive for the BRCA1 mutation; soon after, my twin sister and I were tested for the inherited defective gene, and I learned I, too, have the BRCA1 mutation. My sister is not a carrier of the mutation. Although there is a long history of both breast and...

The Opioid Crisis as Told From the Streets to the Clinics and Its Unintended Consequences

The history of drug addictions and epidemics in the United States dates back to the Civil War, when morphine was introduced as a pain medication for wounded soldiers. Regular off-label use of morphine quickly spread from war hospitals to the general public. It is estimated that more than 400,000...

A Cello for Michayla

The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...

colorectal cancer

Expert Point of View: John M. Carethers, MD

The analysis of the National Cancer Database is one of a number of studies describing  sociodemographic-related disparities in colorectal cancer outcomes, according to session Co-Chair John M. Carethers, MD, Professor and Chair of the Department of Internal Medicine at the University of Michigan,...

Veterans Health Bill Promotes Comprehensive Prostate Cancer Care Program

The American Urological Association (AUA) ­announced its support for the Veterans Prostate Cancer Treatment and Research Act, introduced on March 5 by Rep. Neal Dunn, MD (R-FL-3), and Rep. Joe Cunningham (D-SC-1). This bill supports the development and implementation of a Veterans Health...

Randall A. Oyer, MD, Named President of the Association of Community Cancer Centers

At the Association of Community Cancer Centers (ACCC) 46th Annual Meeting & Cancer Center Business Summit, held March 4–6 in Washington, DC, Randall A. Oyer, MD, was named ACCC President for 2020–2021. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the ...

International Association for the Study of Lung Cancer Names Research Award After Fred R. Hirsch, MD, PhD

The International Association for the Study of Lung Cancer (IASLC) recently announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC Chief Executive Officer Fred R. Hirsch, MD, PhD. The award, which was previously named after Adi Gazdar, MD, who...

Charles Sawyers, MD, Receives Knudson Award in Cancer Genetics

The National Cancer Institute (NCI) has named Charles Sawyers, MD, as the recipient of the 2020 Alfred G. Knudson Award in Cancer Genetics. Dr. Sawyers is Chair of the Human Oncology and Pathogenesis Program and the Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, as ...

Memorial Sloan Kettering Announces Two New Appointments

Memorial Sloan Kettering Cancer Center (MSK) recently appointed Sergio Giralt, MD, and Miguel-Angel Perales, MD, as Deputy Division Head of the Division of Hematologic Malignancies and Chief of the Adult Bone Marrow Transplant Service, respectively. Dr. Giralt: New Roles and Old Former Chief of...

issues in oncology

Cancer During Pregnancy: Whose Moral Compass to Follow?

As has often been written, “Cancer is the greatest equalizer.” It tends to strike its victims regardless of their financial status. In low- and middle-income countries, however, the impact of poverty on the treatment of cancer is strikingly conspicuous. It is the major catalyst for delay in seeking ...

issues in oncology
survivorship

How Exercise Oncology Can Improve Cancer Outcome and Survivorship

Researchers from the American College of Sports Medicine (ACSM) recently reviewed hundreds of epidemiologic studies on the link between physical activity and both cancer risk and cancer mortality. A subsequent analysis of the findings by a panel of experts representing 17 partner organizations,...

covid-19

Oncologists on the Front Lines of COVID‑19

Coronavirus disease 2019 (COVID-19) is dramatically affecting health-care systems. This is the first in a series of interviews The ASCO Post will conduct with oncologists, to learn what they and their cancer centers are doing to deal with the crisis. In this article, we talk with John Cole, MD, a...

issues in oncology
prostate cancer
lung cancer
breast cancer
colorectal cancer

Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation

People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session (Abstract 1216-235). In...

covid-19

A Message From the FDA OCE for Patients With Cancer and Health-Care Providers on COVID-19

On March 23, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) issued the following statement: The FDA OCE recognizes that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease (COVID-19). While everyone’s daily lives...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Phase III JAVELIN Gastric 100 Trial Finds No Survival Benefit for Maintenance Avelumab

In the phase III JAVELIN Gastric 100 trial, a strategy called “switch maintenance” with the immune checkpoint inhibitor avelumab after 12 weeks of first-line induction chemotherapy did not statistically improve overall survival for treatment-naive patients with HER2-negative advanced gastric or...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Pembrolizumab in MSI-H and CPS ≥ 10 Advanced Gastric or Gastroesophageal Junction Cancer: Subanalysis of KEYNOTE-059, -061, and -062

The survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a combined positive score (CPS) ≥ 10 was established in post hoc subanalysis of three KEYNOTE trials. Findings were presented at the 2020...

pancreatic cancer

Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO

Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free and overall survival data—these data are...

pancreatic cancer

Cisplatin/Gemcitabine Alone and With Veliparib in BRCA-Mutated Advanced Pancreatic Cancer

In patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, first-line therapy with cisplatin plus gemcitabine yielded high response rates and encouraging survival, according to Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented the findings...

pancreatic cancer
genomics/genetics

Genetic Counseling and Testing of Patients With Pancreatic Cancer

Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute in Boston, the use of a systemized, automated referral system ...

Advertisement

Advertisement




Advertisement